乳腺癌患者大分割放疗后放射性甲状腺功能减退的前瞻性队列研究
该前瞻性队列纳入500例接受大分割放疗的乳腺癌患者,中位随访21.9个月,26.2%发生放射性甲状腺功能减退(RHT),11.8%接受甲状腺激素替代治疗。锁骨上淋巴结放疗者2年累积发生率31.5% vs 未放疗者11.4%(P<.001)。基线TSH升高和甲状腺平均剂量(Dmean)是独立危险因素,Dmean>21 Gy为预测阈值(HR 2.2,P<.001)。
要点
- 乳腺癌大分割放疗后RHT发生率为26.2%,中位随访21.9个月。
- 锁骨上淋巴结放疗者2年RHT累积发生率31.5%,显著高于未放疗者的11.4%。
- 甲状腺Dmean>21 Gy是RHT预测阈值,风险比为2.2。
核心结论
- 乳腺癌患者大分割放疗后RHT发生率较高。
- 甲状腺功能检测应在放疗后不晚于6个月开始。
- 推荐大分割放疗时甲状腺Dmean保持在21 Gy以下。
研究设计与样本
- 前瞻性队列研究,纳入500例接受大分割放疗的乳腺癌患者。
- 放疗前及放疗后定期进行甲状腺功能检测。
- RHT定义为放疗后两次血清促甲状腺激素(TSH)升高,伴游离甲状腺素降低或正常。
主要发现
- 500例患者中,369例(73.8%)接受锁骨上淋巴结放疗(SCRT),82例(16.4%)放疗前TSH升高。
- 中位随访21.9个月,131例(26.2%)发生RHT,59例(11.8%)接受甲状腺激素替代治疗。
- SCRT组2年RHT累积发生率为31.5%,无SCRT组为11.4%(P<.001)。
- RHT发病高峰在放疗后约6至12个月。
- 多因素分析显示,基线TSH升高和甲状腺Dmean增加是RHT的独立危险因素;校正基线TSH后,甲状腺Dmean与RHT风险呈非线性关系,Dmean>21 Gy为预测RHT的阈值(风险比2.2,P<.001)。
关键数值与推荐
- RHT定义为放疗后两次血清TSH升高,伴游离甲状腺素降低或正常。
- 甲状腺Dmean>21 Gy预测RHT的风险比为2.2(P<.001)。
- SCRT组2年RHT累积发生率为31.5%,无SCRT组为11.4%(P<.001)。
临床怎么用
- 作者建议甲状腺功能检测应在放疗后不晚于6个月开始。
- 作者推荐大分割放疗时甲状腺Dmean应保持在21 Gy以下。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our objective was to assess the incidence and risk factors of radiation-induced hypothyroidism (RHT) after adjuvant hypofractionated radiation therapy (RT) in patients with breast cancer. METHODS AND MATERIALS: Eligible patients with breast cancer who were treated with hypofractionated RT were prospectively evaluated. Thyroid function tests were performed before and at regular times after RT. RHT was defined as twice elevated serum thyroid-stimulating hormone (TSH) with decreased or normal free thyroxin after RT. The patient, tumor, and treatment factors were evaluated for possible associations with the risk of RHT. RESULTS: Five hundred patients were analyzed. All patients underwent chest wall/breast with or without regional nodal irradiation. Among them, 369 (73.8%) patients received supraclavicular nodal radiation (SCRT). Eighty-two (16.4%) patients had elevated TSH before RT. At a median follow-up of 21.9 months, 131 (26.2%) patients developed RHT, and 59 (11.8%) patients received thyroid hormone-replacement therapy. Patients with SCRT had a significantly increased 2-year cumulative incidence of RHT compared with patients without SCRT (31.5% and 11.4%, P<.001). The peak incidence of RHT occurred around 6 to 12 months after RT. Multivariate analysis revealed that elevated baseline TSH and increased thyroid mean dose (Dmean) were independent risk factors for developing RHT. After adjusted for baseline TSH, there was a nonlinear relationship between thyroid Dmean and the risk of RHT. Dmean >21 Gy was the threshold value for predicting RHT (hazard ratio, 2.2; P<.001). CONCLUSIONS: The incidence of RHT was high in patients with breast cancer. Thyroid function test should be started no later than 6 months after RT. We recommend that the Dmean of the thyroid should be kept lower than 21 Gy for hypofractionated RT.
引用
- Zhao XR, Fang H, Jing H, et al. Radiation-Induced Hypothyroidism in Patients With Breast Cancer After Hypofractionated Radiation Therapy: A Prospective Cohort Study. Int J Radiat Oncol Biol Phys. 2022. PMID: 36306978. doi:10.1016/j.ijrobp.2022.04.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。